A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Roche

Status and phase: Terminated; Phase 2

Conditions: Multiple Myeloma

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT02079519

ML18704

Details and patient eligibility

About

This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.

Enrollment: 10 patients

Sex: All

Ages: 19 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, 19-75 years of age
• Multiple myeloma.
• Progressive disease after at least 2 lines of prior therapy.

Exclusion criteria

• Non-secretory myeloma.
• History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer in situ of the cervix within the last 5 years.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start.
• Clinically significant cardiac disease.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Bevacizumab 5 mg/kg

Experimental group

Description:

Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.

Treatment:

Drug: Bevacizumab